Selvita delivered on both fronts in 2016. We expect sales to have grown a solid 21% y-o-y, with an R&D milestone met and the FDA accepting an investigational new drug application for the company’s lead drug candidate, SEL24, which now proceeds through Phase I/II. We have increased our valuation to PLN577m, which includes the first stage of Selvita’s long-term expansion plans. Continued organic growth and potential collaboration deals for Selvita’s innovation platform are
20 Mar 2017
SEL24 enters Phase I/II
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SEL24 enters Phase I/II
Ryvu Therapeutics SA (RVU:WAR) | 0 0 0.0%
- Published:
20 Mar 2017 -
Author:
Dr Jonas Peciulis -
Pages:
13
Selvita delivered on both fronts in 2016. We expect sales to have grown a solid 21% y-o-y, with an R&D milestone met and the FDA accepting an investigational new drug application for the company’s lead drug candidate, SEL24, which now proceeds through Phase I/II. We have increased our valuation to PLN577m, which includes the first stage of Selvita’s long-term expansion plans. Continued organic growth and potential collaboration deals for Selvita’s innovation platform are